Precipio (NASDAQ:PRPO) Stock Price Passes Above 200 Day Moving Average – Should You Sell?
by Amy Steele · The Cerbat GemPrecipio, Inc. (NASDAQ:PRPO – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $24.78 and traded as high as $29.08. Precipio shares last traded at $28.70, with a volume of 50,416 shares.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on PRPO. Wall Street Zen raised Precipio from a “hold” rating to a “buy” rating in a research note on Saturday, April 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on Precipio
Precipio Stock Performance
The business has a fifty day simple moving average of $27.84 and a two-hundred day simple moving average of $24.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.61 and a quick ratio of 1.36. The company has a market cap of $46.35 million, a PE ratio of -55.40 and a beta of 1.38.
Precipio (NASDAQ:PRPO – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) EPS for the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.81%. The business had revenue of $6.71 million for the quarter.
Institutional Trading of Precipio
Hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new stake in shares of Precipio during the 3rd quarter valued at $194,000. Renaissance Technologies LLC lifted its holdings in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 1,400 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Precipio by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares during the last quarter. Evernest Financial Advisors LLC purchased a new stake in shares of Precipio during the 3rd quarter valued at $374,000. Finally, Topline Capital Management LLC purchased a new stake in shares of Precipio during the 3rd quarter valued at $1,158,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.
Precipio Company Profile
Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.
The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.